{ "dataset": "PeptaHub: Peptide Vendor Landscape Tracker 2026", "description": "Open dataset of dated peptide-market enforcement and shutdown events (2024-2026), each with enforcement channel, event description, status, and evidence-graded sources.", "lastVerified": "2026-10-16", "cadence": "weekly", "license": "CC BY 4.0", "license_url": "https://creativecommons.org/licenses/by/4.0/", "source": "https://peptahub.com/peptide-vendor-tracker", "attribution": "PeptaHub (peptahub.com)", "methodologyNote": "Every event carries at least one source with an evidence grade: primary = regulator/court record (fda.gov, justice.gov, cbp.gov, federalregister.gov, ITC dockets); secondary = named press or legal-industry analysis; reported = single-source or uncorroborated account carried pending primary re-location. Sources without a url field are named-but-not-linked (URL not retained at capture time, or a vendor directory this site never links). No ranking, scoring, or evaluation of vendors. See the page methodology for the full editorial rules.", "record_count": 18, "events": [ { "date": "Sep 27, 2026", "event": "Visa notices to underwriting banks precede Chameleon Peptides closure", "channel": "payment-network", "what_happened": "Chameleon Peptides closes after Visa sends notices to its underwriting banks questioning whether the company's sales were reaching only research customers, according to an incumbent vendor-directory account citing an industry email. This is the first entry in this catalog in which a payment network's action, rather than a regulator's or a court's, is reported to have immediately preceded a seller's closure.", "status": "Closed", "sources": [ { "label": "thepeptidecatalog.com closure article (updated Oct 10, 2026), citing a CompoundReview email — named, not linked; see methodology", "url": null, "grade": "reported" } ] }, { "date": "Sep 15, 2026", "event": "Eternal Peptides closes", "channel": "market-exit", "what_happened": "Eternal Peptides ceases operations in a closure reported as voluntary. The only accessible account is an incumbent vendor-directory article; no regulator action or primary record has been located for this closure.", "status": "Closed (thinly sourced)", "sources": [ { "label": "thepeptidecatalog.com closure article — named, not linked; see methodology", "url": null, "grade": "reported" } ] }, { "date": "Aug 24, 2026", "event": "FDA warns 'research use only' peptide sellers", "channel": "fda-letter", "what_happened": "The FDA issues warning letters to at least four sellers marketing peptides 'for research use only': NuScience Peptides LLC, Royal Peptides, Peptide Partners, and Peak Peptides. The NuScience letter (MARCS-CMS 733652), captured verbatim, cites nine products — including a 'GLP-2 Tirz Peptide', retatrutide, and tesamorelin blends — as unapproved new drugs under section 505(a), issued over the signature of the Director of CDER's Office of Unapproved Drugs and Labeling Compliance. A possible fifth letter to another seller was reported but unconfirmed at capture time.", "status": "Letters issued", "sources": [ { "label": "FDA warning letter — NuScience Peptides LLC (MARCS-CMS 733652)", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026", "grade": "primary" }, { "label": "Sheppard Mullin client alert on the Aug 24, 2026 letters (Sep 18, 2026)", "url": null, "grade": "secondary" }, { "label": "McDermott Will & Emery — RUO crackdown analysis (Sep 2026)", "url": null, "grade": "secondary" } ] }, { "date": "Jul 30–31, 2026", "event": "Paradigm Peptides operators sentenced — 70 and 16 months", "channel": "doj-prosecution", "what_happened": "Owner Matthew Kawa is sentenced to 70 months in prison and a co-defendant to 16 months, following guilty pleas to distributing unapproved drugs and illegal importation, in the U.S. Attorney's case (Northern District of Indiana) that ended Paradigm Peptides. The DOJ release's title and date are confirmed via search results and an accessible secondary report; the release body was not machine-fetchable at verification. The forfeiture amount (reported at roughly $5 million) and the product-adulteration details (forged lab certificates; testosterone found in products) trace to secondary summaries and ship at the lowest grade, not as primary-verified facts.", "status": "Sentenced", "sources": [ { "label": "DOJ USAO-NDIN press release — Illinois man and Indiana woman sentenced (Jul 31, 2026)", "url": "https://www.justice.gov/usao-ndin/pr/illinois-man-and-indiana-woman-sentenced-respectively-70-months-and-16-months-prison", "grade": "primary" }, { "label": "CBS News — Paradigm Peptides sentencing report (Jul 30, 2026)", "url": null, "grade": "secondary" }, { "label": "thepeptidecatalog.com closure article (forfeiture and adulteration details) — named, not linked; see methodology", "url": null, "grade": "reported" } ] }, { "date": "Jul 1, 2026", "event": "Strate Labs winds down after Eli Lilly ITC default", "channel": "private-litigation", "what_happened": "Strate Labs announces a voluntary wind-down, citing a shifted regulatory landscape. The company was the defaulted respondent in Eli Lilly's International Trade Commission complaint over tirzepatide, with a cease-and-desist order issued against it. This is the first entry in this catalog in which a brand-name manufacturer's private action, rather than an FDA or DOJ action, preceded a peptide seller's exit.", "status": "Wound down", "sources": [ { "label": "thepeptidecatalog.com closure article, citing the ITC docket — named, not linked; see methodology", "url": null, "grade": "reported" } ] }, { "date": "~Jun 2026", "event": "FDA warns 25 more telehealth companies over compounded-GLP-1 promotion", "channel": "fda-letter", "what_happened": "The FDA sends approximately 25 additional warning letters to telehealth companies over compounded GLP-1 promotion, extending the March 2026 telehealth warning campaign. Documented via legal-industry analysis and the FDA's own social accounts; the letter list had not been re-located on fda.gov at verification time.", "status": "Letters issued", "sources": [ { "label": "Sheppard Mullin client alert on the June 2026 telehealth letters", "url": null, "grade": "secondary" } ] }, { "date": "Mar 31, 2026", "event": "Gram Peptides warning letter (MARCS-CMS 721806)", "channel": "fda-letter", "what_happened": "The FDA issues a warning letter to Gram Peptides (MARCS-CMS 721806) following a review of its website beginning January 2026, citing unapproved new drugs. The letter is on fda.gov; its URL was not retained at capture time, so the letter is cited by its MARCS-CMS control number.", "status": "Letter issued", "sources": [ { "label": "FDA warning letter — Gram Peptides (MARCS-CMS 721806; site reviewed from Jan 2026)", "url": null, "grade": "primary" } ] }, { "date": "Mar 6, 2026", "event": "Peptide Sciences shuts down", "channel": "market-exit", "what_happened": "Peptide Sciences, a US research-chemical peptide supplier, posts a closure notice (around 2pm ET) and ceases operations. The closure is voluntary, and no specific enforcement action against the company has been confirmed. Reported context: an estimated ~$7.4M in online sales in December 2025 alone, failed third-party retesting of 37 retatrutide samples, and GLP-1 litigation exposure.", "status": "Closed", "sources": [ { "label": "Lumalex Law — Peptide Sciences analysis (Mar 13, 2026)", "url": null, "grade": "secondary" }, { "label": "r/ScienceBioTechnology — shutdown thread (Mar 2026) — named, not linked; see methodology", "url": null, "grade": "reported" } ] }, { "date": "Mar 3, 2026", "event": "FDA warns 30 telehealth companies over compounded-GLP-1 marketing", "channel": "fda-letter", "what_happened": "The FDA issues warning letters to 30 telehealth companies over false or misleading claims about compounded GLP-1 drugs — a wave aimed at promotion by clinics and platforms rather than at compounders themselves.", "status": "Letters issued", "sources": [ { "label": "FDA press announcement (Mar 3, 2026)", "url": "https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s", "grade": "primary" } ] }, { "date": "Jan 27, 2026", "event": "Science.bio ceases operations", "channel": "market-exit", "what_happened": "Science.bio ceases operations, stating that it will refund outstanding orders and offering no detailed explanation. The closure reads as voluntary; no enforcement action against the company appears in any primary source located for this catalog.", "status": "Closed", "sources": [ { "label": "thepeptidecatalog.com closure article — named, not linked; see methodology", "url": null, "grade": "reported" } ] }, { "date": "Dec 2025", "event": "CBP Cincinnati intercepts 5,000+ unapproved peptide vials", "channel": "cbp-interdiction", "what_happened": "U.S. Customs and Border Protection officers in Cincinnati foil the smuggling of more than 5,000 unapproved peptide vials, interdicting the shipment at the port before domestic distribution. Located via CBP's newsroom; the specific release was surfaced through search results during verification.", "status": "Interdicted", "sources": [ { "label": "CBP newsroom — Cincinnati seizure (Dec 2025)", "url": "https://www.cbp.gov/newsroom", "grade": "primary" } ] }, { "date": "Sep 16, 2025", "event": "FDA sends 55+ warning letters to compounded-GLP-1 sellers", "channel": "fda-letter", "what_happened": "The FDA issues more than 55 warning letters to online sellers of compounded GLP-1 agonists, citing 503A/503B compounding failures — the largest single letter wave in this catalog. An example letter to 'GLP-1 Solution' dated September 9, 2025 is on fda.gov; the wave total is documented by trade press.", "status": "Letters issued", "sources": [ { "label": "FDA warning letter — 'GLP-1 Solution' (Sep 9, 2025), an example of the wave", "url": null, "grade": "primary" }, { "label": "Pharmacy Times — 55+ compounded-GLP-1 letters (Sep 16, 2025)", "url": null, "grade": "secondary" } ] }, { "date": "Sep 2025", "event": "Criminal prosecutions with $1.79M–$3M+ forfeitures", "channel": "doj-prosecution", "what_happened": "PeptaHub's earlier regulatory coverage reported federal prosecutions of peptide sellers concluding with forfeitures ranging from $1.79 million to more than $3 million. The underlying DOJ releases were not re-located during the October 2026 verification pass; this entry is carried on that previously published in-house record pending re-location of the primaries.", "status": "Forfeitures (reported)", "sources": [ { "label": "PeptaHub regulatory timeline (in-house record; DOJ primaries pending re-location)", "url": "https://peptahub.com/regulatory-timeline", "grade": "reported" } ] }, { "date": "Jun 2025", "event": "Federal raid takes Amino Asylum offline", "channel": "doj-prosecution", "what_happened": "Federal agents raid Amino Asylum's warehouse operations across Tennessee and Kentucky; the site goes offline around June 17, 2025 and operations cease. The founders are reported, by a later secondary account, to have pled guilty (July 2026); a relaunch attempt under a different name was reported but not confirmed.", "status": "Closed", "sources": [ { "label": "AMC Defense Law — 'Justice Watch' enforcement review (Mar 24, 2026)", "url": null, "grade": "secondary" }, { "label": "Peptides Enhanced — enforcement review (Jul 2026)", "url": null, "grade": "reported" } ] }, { "date": "Feb 2025", "event": "Warrior Labz operator sentenced (Vermont)", "channel": "doj-prosecution", "what_happened": "Jeremy Brown, operator of Warrior Labz, is sentenced for selling unapproved drugs online, in a DOJ / FDA Office of Criminal Investigations prosecution out of Vermont. Documented via a justice.gov release surfaced in search results; the release URL was not retained at capture time.", "status": "Sentenced", "sources": [ { "label": "DOJ press release — Warrior Labz / Jeremy Brown sentencing (Feb 2025), via justice.gov", "url": null, "grade": "primary" } ] }, { "date": "2025 (undated)", "event": "Four thinly documented 2025 closures", "channel": "market-exit", "what_happened": "Royal Research, Peptide Tech Labs, American Research Labs, and Unchained Compounds stop operating during 2025 under what an incumbent vendor-directory article describes as regulatory pressure. These closures are thinly sourced: the directory article is the only located account, dates are not published, and no primary record has been located for any of the four. They are carried at the lowest evidence grade and named here only as market events.", "status": "Closed (thinly sourced)", "sources": [ { "label": "thepeptidecatalog.com closure article — named, not linked; see methodology", "url": null, "grade": "reported" } ] }, { "date": "Dec 2024", "event": "First warning-letter wave hits gray-market sellers", "channel": "fda-letter", "what_happened": "The FDA issues warning letters to Summit Research Peptides, Prime Peptides, Xcel Peptides, and SwissChems for selling unapproved new drugs — the earliest warning-letter wave in this catalog. The letters are on fda.gov; their URLs were not retained during the October 2026 pass, so this entry carries the in-house record.", "status": "Letters issued", "sources": [ { "label": "PeptaHub regulatory timeline (in-house record; letters on fda.gov, URLs not retained this pass)", "url": "https://peptahub.com/regulatory-timeline", "grade": "reported" } ] }, { "date": "Mar 2024", "event": "Paradigm Peptides closes as owner is charged", "channel": "doj-prosecution", "what_happened": "Paradigm Peptides ceases operations after its owner is charged in the Northern District of Indiana case that ends with the July 2026 sentencings. The case's full arc — from these 2024 charges to a 70-month sentence — spans the entire period this tracker covers.", "status": "Closed; owner sentenced Jul 2026", "sources": [ { "label": "DOJ USAO-NDIN — U.S. v. Kawa case record (2024 charges through Jul 2026 sentencing)", "url": "https://www.justice.gov/usao-ndin/pr/illinois-man-and-indiana-woman-sentenced-respectively-70-months-and-16-months-prison", "grade": "primary" } ] } ] }